525 related articles for article (PubMed ID: 25043018)
21. Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.
Jaenicke LA; von Eyss B; Carstensen A; Wolf E; Xu W; Greifenberg AK; Geyer M; Eilers M; Popov N
Mol Cell; 2016 Jan; 61(1):54-67. PubMed ID: 26687678
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.
Mishra R; Watanabe T; Kimura MT; Koshikawa N; Ikeda M; Uekusa S; Kawashima H; Wang X; Igarashi J; Choudhury D; Grandori C; Kemp CJ; Ohira M; Verma NK; Kobayashi Y; Takeuchi J; Koshinaga T; Nemoto N; Fukuda N; Soma M; Kusafuka T; Fujiwara K; Nagase H
Cancer Sci; 2015 Apr; 106(4):421-9. PubMed ID: 25611295
[TBL] [Abstract][Full Text] [Related]
23. Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma.
Lu L; Han H; Tian Y; Li W; Zhang J; Feng M; Li Y
Mol Carcinog; 2015 Nov; 54(11):1467-79. PubMed ID: 25284017
[TBL] [Abstract][Full Text] [Related]
24. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
25. Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells.
Wiese KE; Haikala HM; von Eyss B; Wolf E; Esnault C; Rosenwald A; Treisman R; Klefström J; Eilers M
EMBO J; 2015 Jun; 34(11):1554-71. PubMed ID: 25896507
[TBL] [Abstract][Full Text] [Related]
26. Restriction of memory B cell differentiation at the germinal center B cell positive selection stage.
Toboso-Navasa A; Gunawan A; Morlino G; Nakagawa R; Taddei A; Damry D; Patel Y; Chakravarty P; Janz M; Kassiotis G; Brink R; Eilers M; Calado DP
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32407433
[TBL] [Abstract][Full Text] [Related]
27. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
28. Widespread microRNA repression by Myc contributes to tumorigenesis.
Chang TC; Yu D; Lee YS; Wentzel EA; Arking DE; West KM; Dang CV; Thomas-Tikhonenko A; Mendell JT
Nat Genet; 2008 Jan; 40(1):43-50. PubMed ID: 18066065
[TBL] [Abstract][Full Text] [Related]
29. Menin enhances c-Myc-mediated transcription to promote cancer progression.
Wu G; Yuan M; Shen S; Ma X; Fang J; Zhu L; Sun L; Liu Z; He X; Huang D; Li T; Li C; Wu J; Hu X; Li Z; Song L; Qu K; Zhang H; Gao P
Nat Commun; 2017 May; 8():15278. PubMed ID: 28474697
[TBL] [Abstract][Full Text] [Related]
30. c-MYC repression of promoter activity through core promoter elements.
Lucas JM; Wilkie NM; Lang JC
Biochem Biophys Res Commun; 1993 Aug; 194(3):1446-52. PubMed ID: 8352803
[TBL] [Abstract][Full Text] [Related]
31. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation.
Vartanian R; Masri J; Martin J; Cloninger C; Holmes B; Artinian N; Funk A; Ruegg T; Gera J
Mol Cancer Res; 2011 Jan; 9(1):115-30. PubMed ID: 21135252
[TBL] [Abstract][Full Text] [Related]
32. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.
Wang B; Hsu SH; Wang X; Kutay H; Bid HK; Yu J; Ganju RK; Jacob ST; Yuneva M; Ghoshal K
Hepatology; 2014 Feb; 59(2):555-66. PubMed ID: 24038073
[TBL] [Abstract][Full Text] [Related]
33. c-MYC targets the central oscillator gene Per1 and is regulated by the circadian clock at the post-transcriptional level.
Repouskou A; Prombona A
Biochim Biophys Acta; 2016 Apr; 1859(4):541-52. PubMed ID: 26850841
[TBL] [Abstract][Full Text] [Related]
34. Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo.
Strobl LJ; Eick D
EMBO J; 1992 Sep; 11(9):3307-14. PubMed ID: 1505520
[TBL] [Abstract][Full Text] [Related]
35. Loss of MYC and E-box3 binding contributes to defective MYC-mediated transcriptional suppression of human MC-let-7a-1~let-7d in glioblastoma.
Wang Z; Lin S; Zhang J; Xu Z; Xiang Y; Yao H; Ge L; Xie D; Kung HF; Lu G; Poon WS; Liu Q; Lin MC
Oncotarget; 2016 Aug; 7(35):56266-56278. PubMed ID: 27409345
[TBL] [Abstract][Full Text] [Related]
36. Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters.
Yap CS; Peterson AL; Castellani G; Sedivy JM; Neretti N
Cell Cycle; 2011 Jul; 10(13):2184-96. PubMed ID: 21623162
[TBL] [Abstract][Full Text] [Related]
37. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
[TBL] [Abstract][Full Text] [Related]
38. Ribosomal protein S14 negatively regulates c-Myc activity.
Zhou X; Hao Q; Liao JM; Liao P; Lu H
J Biol Chem; 2013 Jul; 288(30):21793-801. PubMed ID: 23775087
[TBL] [Abstract][Full Text] [Related]
39. Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping.
Hyle J; Zhang Y; Wright S; Xu B; Shao Y; Easton J; Tian L; Feng R; Xu P; Li C
Nucleic Acids Res; 2019 Jul; 47(13):6699-6713. PubMed ID: 31127282
[TBL] [Abstract][Full Text] [Related]
40. MYCT1-TV, a novel MYCT1 transcript, is regulated by c-Myc and may participate in laryngeal carcinogenesis.
Fu S; Guo Y; Chen H; Xu ZM; Qiu GB; Zhong M; Sun KL; Fu WN
PLoS One; 2011; 6(10):e25648. PubMed ID: 21998677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
